XXXX interference with opiate urine drug screen.

@entity1 @entity7046 @entity137 @entity2887 @entity293
A 48-year-old @entity1 participating in a residential treatment program was treated with @entity7046 for a @entity293 . While taking the antibiotic, two urine screens were positive for opiates; results of previous urine opiate screens had been negative. Confirmatory tests using a different assay method, however, gave negative results for opiates. Two weeks after completing @entity7046 therapy, the @entity1 's urine screen was negative for opiates. Application of the Naranjo @entity137 probability scale indicated that @entity7046 probably was associated with this @entity1 's positive urine opiate screen. @entity2887 as a class are among several compounds that have demonstrated a propensity to cross-react with enzyme immunoassay urine drug screens for opiates. Occurrence of cross-reactivity appears to vary among individual assays. The mechanism by which @entity2887 cross-react with the immunoassay is unknown. Falsepositive results could have negative effects on @entity1 care, and ramifications of a positive drug screen include possible dismissal from a substance abuse treatment program. Confirmatory analysis using a different assay method is therefore necessary to verify the presence of the target drug.
